Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sorbitol is a six-carbon sugar alcohol (polyol) that occurs naturally in various fruits and is widely used as a bulk sweetener, humectant, and pharmaceutical excipient. Therapeutically, it is primarily utilized as an osmotic laxative, administered either orally or rectally to treat constipation by increasing intraluminal water retention and stimulating peristalsis. Beyond its traditional use, sorbitol is being investigated for its metabolic effects, such as the induction of fibroblast growth factor 21 (FGF21) to suppress sugar appetite and prevent obesity. Additionally, clinical research is exploring the use of sorbitol-supplemented diets to enhance the efficacy of neoadjuvant chemoimmunotherapy in locally advanced gastric cancer by modulating the polyol pathway and immune response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sorbitol.